Last reviewed · How we verify
Visceral leishmaniasis
Approved treatments
- Abelcet · Astellas Pharma
- Impavido · Knight Theraps
Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Visceral leishmaniasis patent landscape — cliff calendar, originator estates, attackable patents
- Visceral leishmaniasis treatment landscape brief
- Visceral leishmaniasis treatment updates RSS
Frequently asked questions about Visceral leishmaniasis
What drugs treat Visceral leishmaniasis?
Tracked treatments include Abelcet, Impavido.
What is the treatment for Visceral leishmaniasis?
Standard treatment for Visceral leishmaniasis includes Abelcet, Impavido. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Visceral leishmaniasis patent cliff · Visceral leishmaniasis CI report
- Treatment: Abelcet · Astellas Pharma
- Treatment: Impavido · Knight Theraps
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing